<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077699</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-DG 10</org_study_id>
    <nct_id>NCT02077699</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study</brief_title>
  <official_title>Valutazione Dell'Efficacia Di Una Preparazione Commerciale A Base Di Lactobacillus Casei Dg Nella Riduzione Della Sintomatologia Dolorosa Associata Alla Sindrome Dell' Intestino Irritabile (Sii). Studio Clinico Pilota. (Official Title in Italian Language)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOFAR S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOFAR S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of a treatment with Lactobacillus casei
      DG in the reduction of the painful symptoms in patients affected by irritable bowel syndrome.
      After that, the secondary object is to evaluate if the reduction of painful symptoms is
      related to a relevant reduction of trypsin and tryptase in colonic mucosa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of painful symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <description>The efficacy of the treatment will be evaluated recording the intensity of the painful symptoms associated with irritable bowel syndrome for the duration of the study. The intensity of abdominal pain will be recorded daily by the patient in a diary using a semi-quantitative scale (Likert) to 6 points, from 0 (absent) to 5 (very severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of trypsin and tryptase in colonic mucosa</measure>
    <time_frame>4 weeks</time_frame>
    <description>Will evaluate the reduction in the levels of trypsin and tryptase in the colonic mucosa by collecting biopsies from the sigmoid colon and samples colonic lavage fluid and subsequent histological and molecular examination with extraction of m-RNA and proteins.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Lactobacillus casei DG (24 billion of live cells per pill) 2 pills b.i.d. for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus casei DG</intervention_name>
    <description>Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Enterolactis plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  out-Patients with diagnosis of Irritable Bowel syndrome (IBS) according to Rome III
             Diagnostic Criteria for Functional Gastrointestinal Disorders

          -  Previous colonoscopy (within 24 month prior the enrollment) with negative results

          -  written informed consent

        Exclusion Criteria:

          -  systemic or topical therapy with steroids and glucocorticoids such as beclomethasone
             dipropionate or budesonide, ongoing or within a month prior the enrollment

          -  therapy with antibiotics or probiotics, ongoing or within a month prior the enrollment

          -  inflammatory bowel diseases

          -  copro-paraxitological examination with positive results

          -  bowel disease with infectious, actinic, endocrine or drug-related origin

          -  immunodeficiency

          -  diagnosis of malignant cancer within 5 years prior the enrollment

          -  renal, hepatic, hematologic, cardiovascular, pulmonary, neurological, psychiatric,
             immunological, gastrointestinal or endocrine disorders, if found to be clinically
             relevant

          -  any severe disease that may interfere with the treatment;

          -  abuse of alcohol, drugs or medication, psychotropic drugs

          -  diagnosis of dementia or other disorders that can cause a progressive deterioration of
             capacity of discernment or mental and physical disability which reduces the ability to
             follow the prescribed therapy;

          -  previous participation in this study

          -  pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Monteleone, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Tor Vergata</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UOC di Gastroenterologia - Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005 Jun 1;21(11):1365-75.</citation>
    <PMID>15932367</PMID>
  </reference>
  <reference>
    <citation>Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, MÃ¼ller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999 Sep;45 Suppl 2:II43-7. Review.</citation>
    <PMID>10457044</PMID>
  </reference>
  <reference>
    <citation>Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009 Feb;104(2):404-10. doi: 10.1038/ajg.2008.86. Epub 2009 Jan 20.</citation>
    <PMID>19174795</PMID>
  </reference>
  <reference>
    <citation>Salzmann JL, Peltier-Koch F, Bloch F, Petite JP, Camilleri JP. Morphometric study of colonic biopsies: a new method of estimating inflammatory diseases. Lab Invest. 1989 Jun;60(6):847-51.</citation>
    <PMID>2733385</PMID>
  </reference>
  <reference>
    <citation>O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000 Oct;12(5):449-57.</citation>
    <PMID>11012945</PMID>
  </reference>
  <reference>
    <citation>Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004 Mar;126(3):693-702.</citation>
    <PMID>14988823</PMID>
  </reference>
  <reference>
    <citation>Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut. 2003 Apr;52(4):523-6.</citation>
    <PMID>12631663</PMID>
  </reference>
  <reference>
    <citation>Fahlgren A, Hammarstrom S, Danielsson A, Hammarstrom ML. beta-Defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin Exp Immunol. 2004 Aug;137(2):379-85.</citation>
    <PMID>15270856</PMID>
  </reference>
  <reference>
    <citation>O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005 Mar;128(3):541-51.</citation>
    <PMID>15765388</PMID>
  </reference>
  <reference>
    <citation>Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999 Aug 21;354(9179):635-9.</citation>
    <PMID>10466665</PMID>
  </reference>
  <reference>
    <citation>Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999 Aug;13(8):1103-8.</citation>
    <PMID>10468688</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>November 27, 2014</last_update_submitted>
  <last_update_submitted_qc>November 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lactobacillus casei DG</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

